Amgen Expands R&D C-Suite As Reese Focuses On Technology, Bradner Leads R&D

Former Novartis Exec Rejoins Biopharma Industry

Amgen appointed R&D head David Reese as EVP and chief technology officer and recruited former Novartis executive Jay Bradner as EVP of R&D and chief scientific officer.

Amgen Inc logo magnified on display screen.
Reese will focus on implementing new R&D-enabling technologies • Source: Shutterstock

Amgen, Inc. has doubled the leadership of its research and development efforts, announcing on 14 December that it recruited former Novartis Institutes for BioMedical Research Inc. (NIBR) president Jay Bradner to serve as executive vice president of R&D and chief scientific officer. Current EVP of R&D David Reese remains in the company’s C-suite as executive vice president and chief technology officer.

Bradner’s addition to Amgen’s leadership team comes at a crucial time for the company as it continues to work its way through several big losses of exclusivity for past blockbusters such as Neulasta (pegfilgrastim) and anticipates LOEs later in this decade for additional top sellers, like Prolia (denosumab), while launching multiple new products, including asthma therapy Tezspire (tezepelumab) and KRAS G12C inhibitor Lumakras (sotorasib) for lung cancer. R&D output is a major focus for Amgen as it aims to grow revenue going forward

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Leadership

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By 

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Lundbeck Lifted By Leap In Migraine Therapy Sales

 
• By 

Vyepti revenues rise by nearly 70% in the first quarter.

More from Scrip

Regeneron Wins PCSK9 Court Battle Against Amgen

 

A federal court jury found Amgen liable for violating antitrust laws in allegedly preventing Praluent from competing against Repatha.

Lupin CEO On Trump’s Most Favored Nation Policy, Tariffs, Firm’s Five-Year Plan

 
• By 

Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 

Company surprises investors with Jørgensen's exit but insists its strategy will not change.